PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

Healthcare is supposed to be defensive. When tech stocks swing wildly and consumer spending wobbles, healthcare companies keep selling drugs, performing surgeries, and processing insurance claims. That steady demand makes the sector attractive when investors want growth without the full roller coaster. But what if you could get healthcare exposure with a more concentrated bet on the companies actually driving innovation rather than just riding sector momentum?

That’s where Simplify Health Care ETF (NYSEARCA:PINK) comes in. It’s not trying to own every healthcare stock. It’s trying to own the right ones.

What PINK Actually Does in a Portfolio

PINK is a concentrated healthcare play built for investors who want exposure to pharma innovation, biotech breakthroughs, and medical device leaders without diluting returns across the entire sector. With 60 holdings and nearly 90% allocated to healthcare, this isn’t a diversified fund. It’s a precision tool.

PINK takes a concentrated approach with just 60 holdings focused almost exclusively on healthcare innovation. The fund’s conviction shows in its top positions, where Eli Lilly and Co (NYSE:LLY | LLY Price Prediction) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) together represent over 15% of assets. This concentration means the fund’s performance lives or dies by the execution of its largest bets, with the top 10 holdings driving roughly half of all returns.

Performance That Justifies the Bet

PINK has delivered 58% returns since its October 2021 launch, outpacing the Health Care Select Sector SPDR (NYSEARCA:XLV) benchmark by nearly 8 percentage points. That outperformance accelerated over the past year, with PINK’s 26% gain more than doubling XLV’s return. The edge comes from active management by Michael Taylor, who focuses on future-of-healthcare themes rather than passive sector tracking.

The Tradeoffs You Accept

The concentrated approach comes with clear tradeoffs. PINK charges a 0.51% expense ratio, roughly six times XLV’s cost, reflecting the premium for active stock selection. The fund also generates no dividend income, making it purely a capital appreciation play.

PINK works best as a satellite holding for investors who believe healthcare innovation will outpace the broader sector and are willing to accept higher concentration risk for that potential.